CYBERDYNE Inc (CYBQF) Fair Value & Analysis
Healthcare · US · Market cap $394M
CYBERDYNE Inc
CYBQF · US
Fair value as of: Jul 15, 2026
From 18 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $0.1600 to $0.1300 (−18.8%) since Jun 24, 2026. Share price −30.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.07 – $2.05 · fair‑value band $0.0900 – $0.1700 · the $1.30 price screens above the $0.1300 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CYBERDYNE Inc (CYBQF) currently trades at $1.30, while our model-based Fair Value estimate is $0.1300 — implying the stock looks roughly 90.0% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, CYBERDYNE Inc generated revenue of $3.8B at a net margin of 4.0%. Revenue declined 21.6% year over year. It earns a return on equity of 0.4%. The balance sheet holds a net cash position of $8.3B. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.0900 (bear case) to $0.1700 (bull case); at $1.30, the current price sits above that range. The share trades about 37% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside — at -90%, CYBQF screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
CYBERDYNE Inc reported revenue of $3.9B in FY2026 versus $2.2B in FY2022, a compound +15.8%/yr. Reported net income was $154M in FY2026.
Is CYBQF fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €76.90 | €78.64 | +2% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CYBERDYNE Inc (CYBQF) undervalued?
What is the fair value of CYBQF?
What is the quality score of CYBQF?
What is the revenue of CYBERDYNE Inc (CYBQF)?
What is the net profit margin of CYBQF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full CYBERDYNE Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.